Form 8-K - Current report:
SEC Accession No. 0001104659-26-047711
Filing Date
2026-04-23
Accepted
2026-04-23 16:15:37
Documents
12
Period of Report
2026-04-17
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2612461d1_8k.htm   iXBRL 8-K 26041
2 EXHIBIT 17.1 tm2612461d1_ex17-1.htm EX-17.1 3856
  Complete submission text file 0001104659-26-047711.txt   196275

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA bzyr-20260417.xsd EX-101.SCH 3041
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE bzyr-20260417_lab.xml EX-101.LAB 34239
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE bzyr-20260417_pre.xml EX-101.PRE 22376
16 EXTRACTED XBRL INSTANCE DOCUMENT tm2612461d1_8k_htm.xml XML 3185
Mailing Address 9432 KATY FREEWAY HOUSTON TX 77055
Business Address 12000 RICHMOND AVE HOUSTON TX 77082 (713) 335-5697
BURZYNSKI RESEARCH INSTITUTE INC (Filer) CIK: 0000724445 (see all company filings)

EIN.: 760136810 | State of Incorp.: DE | Fiscal Year End: 0228
Type: 8-K | Act: 34 | File No.: 000-23425 | Film No.: 26888845
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)